Background
Chronic HBV and HCV infections are common co-morbidities that can complicate antiretroviral treatment in HIV-infected patients. Information on efficacy and safety are necessary to better define optimal therapeutic options in this population.
Methods
Randomized, open-label prospective study comparing once-daily ATV/r with twice-daily LPV/r, both in combination with once-daily fixed dose combination tenofovir/ emtricitabine in antiretroviral-naive HIV-1 infected subjects. Proportion of subjects with HIV RNA <50 c/mL (confirmed virologic response/CVR), changes in CD4 cell count and lipids from baseline, and adverse events (AEs) through 48 weeks are presented among chronic HBVand/or HCV-infected (Hep+) subjects.
Summary of results
At baseline, 13% of subjects were Hep+ (5% HBV+; 8% HCV+). Overall 9% of females, 14% males, 25% Asians, 15% Blacks, 5% others, and 13% of Whites were Hep+. (Table 1.) Grade 2-4 treatment related hyperbilirubinemia (15% vs. 0) and jaundice (3% vs. 0) were more common on ATV/r. Nausea (8% vs. 2%) and diarrhea (14% vs. 0) were more common on LPV/r. Few SAEs were reported among Hep+ in either treatment arm. Grade 3-4 elevations in liver function tests were reported among the following: 5/60, 8% (ALT), 5/60, 8% (AST) and 23/60, 38% (total bilirubin) in the ATV/r arm and 3/50, 6% (ALT), 0% (AST); 0% (total bilirubin) in the LPV/r arm. (Table 2 .)
Conclusion
Virologic and immunologic response was comparable in Hep+ treated with ATV/r or LPV/r. ATV/r had a more favorable lipid profile (TC, non-HDL, LDL, TG) and fewer gastrointestinal adverse events among Hep+ subjects than LPV/r. While the overall rates of transaminitis in Hep+ were low in this study compared to those observed in other clinical trials, a small number of subjects in the ATV/ r and none on LPV/r had grade 3-4 AST elevations. The cause of this higher proportion in the ATV/r treatment arm among this limited number of subjects is unclear. With close monitoring of liver function tests, ATV/r can be considered as part of HAART among treatment-naive Hep+ patients.
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